Clinical efficacy of secuchiumab in the treatment of moderate to severe plaque psoriasis
Objective To analyze the clinical efficacy of secuchiumab in the treatment of moderate and severe plaque psoriasis.Methods 60 patients with moderate to severe plaque psoriasis admitted to a certain hospital from May 2021 to May 2023 were selected and divided into two groups according to random number table method.The control group(30 cases)received conventional treatment,and the study group(30 cases)received secuchiumab injection treatment.The levels of inflammatory factors,psoriasis lesion area and severity index(PASI),dermatological quality of life index(DLQI),pruritis degree(VAS score)between the two groups before and after treatment and adverse drug reactions were compared.Results Before treatment,there were no significant difference in IL-17,IL-17A and IL-23 levels,PASI scores,DLQI scores and VAS scores between the two groups(P＞0.05).Compared with the control group,the levels of IL-17,IL-17A and IL-23 in the study group were lower after treatment,and the PASI scores,DLQI scores and VAS scores were lower after 4,8 and 16 weeks of treatment(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The treatment of secuchiumab can effectively reduce the inflammatory response,psoriasis lesion area and severity,and the pruritis degree in patients with moderate to severe plaque psoriasis,and improve the quality of life of patients with high safety.
SecuchiumabModerate to severePlaque psoriasisClinical efficacy
万方数据
维普
